Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.

Autor: Afdhal, N.¹ nafdhal@bidmc.harvard.edu, Everson, G. T.², Calleja, J. L.³, McCaughan, G. W.⁴, Bosch, J.^5,6, Brainard, D. M.⁷, McHutchison, J. G.⁷, De‐Oertel, S.⁷, An, D.⁷, Charlton, M.⁸, Reddy, K. R.⁹, Asselah, T.¹⁰, Gane, E.¹¹, Curry, M. P.¹, Forns, X.⁵

Publikováno v: Journal of Viral Hepatitis. Oct2017, Vol. 24 Issue 10, p823-831. 9p.

The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.

Autor: EVERSON, G. T.¹ (AUTHOR), SHIFFMAN, M. L.² (AUTHOR), MORGAN, T. R.^3,4 (AUTHOR), HOEFS, J. C.^3,4 (AUTHOR), STERLING, R. K.² (AUTHOR), WAGNER, D. A.⁵ (AUTHOR), KULIG, C. C.¹ (AUTHOR), CURTO, T. M.⁶ (AUTHOR), WRIGHT, E. C.⁷ (AUTHOR)

Publikováno v: Alimentary Pharmacology & Therapeutics. May2008, Vol. 27 Issue 9, p798-809. 12p. 3 Charts, 2 Graphs.

Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt.

Autor: EVERSON, G. T.¹ (AUTHOR), MARTUCCI, M. A.¹ (AUTHOR), SHIFFMAN, M. L.² (AUTHOR), STERLING, R. K.² (AUTHOR), MORGAN, T. R.^3,4 (AUTHOR), HOEFS, J. C.^3,4 (AUTHOR)

Publikováno v: Alimentary Pharmacology & Therapeutics. Aug2007, Vol. 26 Issue 3, p401-410. 10p. 3 Charts, 5 Graphs.

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

Autor: Forns X, Poordad F, Pedrosa M, Berenguer M, Wedemeyer H, Ferenci P, Shiffman ML, Fried MW, Lovell S, Trinh R, Lopez-Talavera JC, Everson G

Publikováno v: LIVER INTERNATIONAL
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Background & AimsThrombocytopaenia and hypoalbuminaemia are surrogate markers for portal hypertension and hepatic synthetic dysfunction respectively. Patients infected with hepatitis C virus (HCV) with these surrogates have reduced likelihood of sust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::ab6535157887ced34367d65e2d7f89c3
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2731

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

Autor: Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, ELEVATE Study Group […, Akram J, Bessonova E, Bilodeau M, Bloomer J, Botta Fridlund D, Bzowej N, Calmus Y, Carbonell N, Caro Patón A, Cholewinska G, Chuang WL, Colombato L, Colombo M, Craxi A, Di Leo A, Diago M, Dumortier J, Elkasahab M, Everson G, Fallon M, Fedeli G, Finazzi R, Fontanella A, Francavilla A, Gadano A, Gambarin Gelwan M, Gordon F, Graus Morales J, Grieco A, Gugenheim J, Homenda W, Iaquinto G, Kang H, Khan Z, Kuliczkowski K, Kwo P, Lee JH, Lee W, Lee YS, Mazur W, Moreno C, Morozov V, Muñoz A, Navasa Anadón M, Nijhawan S, Pinzello G, Poordad F, Prieto Castillo M, Rafalsky V, Rapaccini G, Regenstein F, Rewak W, Riley T, Ripoll Noiseux C, Rizzetto M, Rodrigo Lopez J, Russo M, Samuel D, Sánchez Antolín G, Satyanaryana R, Savarino V, Shiffman M, Sigal S, Solá Lamoglia R, Sterling R, Tanno H, Te H, Terg R, Thuluvath P, Trepo C, Vargas H, Xiol Quingles X, Zaman A, Fontana R, Kim K, Abrams C, Gish R, Cardenas A, ANDREONE, PIETRO, MAZZELLA, GIUSEPPE

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c4867da64475128d50da54cdaee7f6
http://hdl.handle.net/10807/33915